HEADER TRANSFERASE 18-OCT-16 5M44 TITLE COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A TITLE 2 THIENO[2,3-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT TITLE 3 CONDITIONS COMPND MOL_ID: 1; COMPND 2 MOLECULE: CASEIN KINASE II SUBUNIT ALPHA; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CK II ALPHA; COMPND 5 EC: 2.7.11.1; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: CSNK2A1, CK2A1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS PROTEIN KINASE CK2 CASEIN KINASE 2, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR K.NIEFIND,N.BISCHOFF,S.M.YARMOLUK,V.G.BDZHOLA,A.G.GOLUB,A.O.BALANDA, AUTHOR 2 A.O.PRYKHOD'KO REVDAT 6 17-JAN-24 5M44 1 REMARK REVDAT 5 06-SEP-17 5M44 1 REMARK REVDAT 4 17-MAY-17 5M44 1 JRNL REVDAT 3 10-MAY-17 5M44 1 JRNL REVDAT 2 25-JAN-17 5M44 1 JRNL REVDAT 1 18-JAN-17 5M44 0 JRNL AUTH K.NIEFIND,N.BISCHOFF,A.G.GOLUB,V.G.BDZHOLA,A.O.BALANDA, JRNL AUTH 2 A.O.PRYKHOD'KO,S.M.YARMOLUK JRNL TITL STRUCTURAL HYPERVARIABILITY OF THE TWO HUMAN PROTEIN KINASE JRNL TITL 2 CK2 CATALYTIC SUBUNIT PARALOGS REVEALED BY COMPLEX JRNL TITL 3 STRUCTURES WITH A FLAVONOL- AND A JRNL TITL 4 THIENO[2,3-D]PYRIMIDINE-BASED INHIBITOR. JRNL REF PHARMACEUTICALS V. 10 2017 JRNL REFN ESSN 1424-8247 JRNL PMID 28085026 JRNL DOI 10.3390/PH10010009 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH B.GUERRA,N.BISCHOFF,V.G.BDZHOLA,S.M.YARMOLUK,O.G.ISSINGER, REMARK 1 AUTH 2 A.G.GOLUB,K.NIEFIND REMARK 1 TITL A NOTE OF CAUTION ON THE ROLE OF HALOGEN BONDS FOR PROTEIN REMARK 1 TITL 2 KINASE/INHIBITOR RECOGNITION SUGGESTED BY HIGH- AND LOW-SALT REMARK 1 TITL 3 CK2ALPHA COMPLEX STRUCTURES. REMARK 1 REF ACS CHEM. BIOL. V. 10 1654 2015 REMARK 1 REFN ESSN 1554-8937 REMARK 1 PMID 25961323 REMARK 1 DOI 10.1021/ACSCHEMBIO.5B00235 REMARK 1 REFERENCE 2 REMARK 1 AUTH A.G.GOLUB,V.G.BDZHOLA,N.V.BRIUKHOVETSKA,A.O.BALANDA, REMARK 1 AUTH 2 O.P.KUKHARENKO,I.M.KOTEY,O.V.OSTRYNSKA,S.M.YARMOLUK REMARK 1 TITL SYNTHESIS AND BIOLOGICAL EVALUATION OF SUBSTITUTED REMARK 1 TITL 2 (THIENO[2,3-D]PYRIMIDIN-4-YLTHIO)CARBOXYLIC ACIDS AS REMARK 1 TITL 3 INHIBITORS OF HUMAN PROTEIN KINASE CK2. REMARK 1 REF EUR J MED CHEM V. 46 870 2011 REMARK 1 REFN ISSN 1768-3254 REMARK 1 PMID 21276643 REMARK 1 DOI 10.1016/J.EJMECH.2010.12.025 REMARK 1 REFERENCE 3 REMARK 1 AUTH A.G.GOLUB,V.G.BDZHOLA,Y.V.KYSHENIA,V.M.SAPELKIN, REMARK 1 AUTH 2 A.O.PRYKHOD'KO,O.P.KUKHARENKO,O.V.OSTRYNSKA,S.M.YARMOLUK REMARK 1 TITL STRUCTURE-BASED DISCOVERY OF NOVEL FLAVONOL INHIBITORS OF REMARK 1 TITL 2 HUMAN PROTEIN KINASE CK2. REMARK 1 REF MOL. CELL. BIOCHEM. V. 356 107 2011 REMARK 1 REFN ISSN 1573-4919 REMARK 1 PMID 21735097 REMARK 1 DOI 10.1007/S11010-011-0945-8 REMARK 2 REMARK 2 RESOLUTION. 2.71 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (1.10.1_2155: ???) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.71 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 27.84 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.360 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 3 NUMBER OF REFLECTIONS : 9935 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.223 REMARK 3 R VALUE (WORKING SET) : 0.219 REMARK 3 FREE R VALUE : 0.259 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 9.620 REMARK 3 FREE R VALUE TEST SET COUNT : 956 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 27.8423 - 5.1748 1.00 1380 153 0.2097 0.2482 REMARK 3 2 5.1748 - 4.1116 1.00 1300 149 0.1750 0.2128 REMARK 3 3 4.1116 - 3.5931 1.00 1291 126 0.1903 0.2522 REMARK 3 4 3.5931 - 3.2652 1.00 1267 134 0.2273 0.2663 REMARK 3 5 3.2652 - 3.0314 1.00 1284 108 0.2586 0.2612 REMARK 3 6 3.0314 - 2.8529 1.00 1229 150 0.2765 0.3331 REMARK 3 7 2.8529 - 2.7101 0.98 1228 136 0.3158 0.3555 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.320 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 23.320 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 38.90 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.003 2881 REMARK 3 ANGLE : 0.535 3897 REMARK 3 CHIRALITY : 0.040 401 REMARK 3 PLANARITY : 0.003 501 REMARK 3 DIHEDRAL : 17.009 1721 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 3 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 3 THROUGH 74 ) REMARK 3 ORIGIN FOR THE GROUP (A): -2.1553 22.2033 -29.7082 REMARK 3 T TENSOR REMARK 3 T11: 0.2890 T22: 0.5211 REMARK 3 T33: 0.1782 T12: 0.1800 REMARK 3 T13: -0.0408 T23: -0.0356 REMARK 3 L TENSOR REMARK 3 L11: 0.7859 L22: 1.0122 REMARK 3 L33: 0.8617 L12: 0.3341 REMARK 3 L13: -0.6023 L23: 0.1639 REMARK 3 S TENSOR REMARK 3 S11: -0.3920 S12: -0.0532 S13: 0.1160 REMARK 3 S21: -0.3832 S22: 0.2533 S23: 0.0118 REMARK 3 S31: -0.2996 S32: -0.5632 S33: -0.2941 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 75 THROUGH 129 ) REMARK 3 ORIGIN FOR THE GROUP (A): -4.1249 18.8252 -25.0650 REMARK 3 T TENSOR REMARK 3 T11: 0.3513 T22: 0.3081 REMARK 3 T33: 0.1261 T12: 0.1042 REMARK 3 T13: -0.0047 T23: -0.0443 REMARK 3 L TENSOR REMARK 3 L11: 2.1832 L22: 1.0689 REMARK 3 L33: 1.2721 L12: 0.2969 REMARK 3 L13: -0.2040 L23: -0.0277 REMARK 3 S TENSOR REMARK 3 S11: -0.1618 S12: -0.2522 S13: -0.0560 REMARK 3 S21: 0.6786 S22: -0.0579 S23: 0.1562 REMARK 3 S31: -0.0500 S32: -0.5142 S33: -0.1142 REMARK 3 TLS GROUP : 3 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 130 THROUGH 331 ) REMARK 3 ORIGIN FOR THE GROUP (A): 16.7780 9.5187 -21.8686 REMARK 3 T TENSOR REMARK 3 T11: 0.1796 T22: 0.1197 REMARK 3 T33: 0.2979 T12: 0.0246 REMARK 3 T13: -0.0468 T23: -0.0210 REMARK 3 L TENSOR REMARK 3 L11: 1.1034 L22: 1.8984 REMARK 3 L33: 2.1099 L12: -0.2113 REMARK 3 L13: 0.7629 L23: 0.1294 REMARK 3 S TENSOR REMARK 3 S11: 0.0296 S12: -0.0606 S13: -0.1211 REMARK 3 S21: 0.0785 S22: 0.0896 S23: -0.7389 REMARK 3 S31: 0.1748 S32: 0.0780 S33: 0.0526 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5M44 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 18-OCT-16. REMARK 100 THE DEPOSITION ID IS D_1200001891. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 20-JAN-12 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 HF REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54179 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 9935 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.710 REMARK 200 RESOLUTION RANGE LOW (A) : 28.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 6.900 REMARK 200 R MERGE (I) : 0.13100 REMARK 200 R SYM (I) : 0.13100 REMARK 200 FOR THE DATA SET : 15.7500 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.71 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.81 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.0 REMARK 200 DATA REDUNDANCY IN SHELL : 5.90 REMARK 200 R MERGE FOR SHELL (I) : 0.80840 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.320 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHENIX REMARK 200 STARTING MODEL: 3NSZ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 42.30 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.13 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PROTEIN STOCK SOLUTION: 6 MG/ML REMARK 280 CK2ALPHA1-335 IN 0.5 M NACL, 25 MM TRIS/HCL, PH 8.5; INHIBITOR REMARK 280 STOCK SOLUTION: 10 MM INHIBITOR IN DMSO; PROTEIN/INHIBITOR REMARK 280 COMPLEX SOLUTION: 90 MICROLITER PROTEIN STOCK SOLUTION + 10 REMARK 280 MICROLITER INHIBITOR STOCK SOLUTION; RESERVOIR SOLUTION: 4.2 M REMARK 280 NACL, 0.1 M SODIUM CITRATE, PH 5.0; DROP SOLUTION BEFORE REMARK 280 EQULIBRATION: 0.5 MICROLITER PROTEIN/INHIBITOR COMPLEX SOLUTION + REMARK 280 0.5 MICROLITER RESERVOIR SOLUTION, VAPOR DIFFUSION, SITTING REMARK 280 DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 43 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -Y+1/2,X+1/2,Z+3/4 REMARK 290 4555 Y+1/2,-X+1/2,Z+1/4 REMARK 290 5555 -X+1/2,Y+1/2,-Z+3/4 REMARK 290 6555 X+1/2,-Y+1/2,-Z+1/4 REMARK 290 7555 Y,X,-Z REMARK 290 8555 -Y,-X,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 65.78950 REMARK 290 SMTRY1 3 0.000000 -1.000000 0.000000 36.03050 REMARK 290 SMTRY2 3 1.000000 0.000000 0.000000 36.03050 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 98.68425 REMARK 290 SMTRY1 4 0.000000 1.000000 0.000000 36.03050 REMARK 290 SMTRY2 4 -1.000000 0.000000 0.000000 36.03050 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 32.89475 REMARK 290 SMTRY1 5 -1.000000 0.000000 0.000000 36.03050 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 36.03050 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 98.68425 REMARK 290 SMTRY1 6 1.000000 0.000000 0.000000 36.03050 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 36.03050 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 32.89475 REMARK 290 SMTRY1 7 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY2 7 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 65.78950 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 680 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 15480 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -55.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 SER A 2 REMARK 465 ALA A 332 REMARK 465 ARG A 333 REMARK 465 MET A 334 REMARK 465 GLY A 335 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU A 45 -63.26 -93.88 REMARK 500 PRO A 72 75.87 -61.97 REMARK 500 SER A 106 61.06 60.68 REMARK 500 ARG A 107 82.26 55.72 REMARK 500 TYR A 125 -149.65 -120.18 REMARK 500 THR A 127 35.28 -99.85 REMARK 500 ASP A 156 45.40 -150.16 REMARK 500 ASP A 175 79.02 54.47 REMARK 500 ARG A 191 48.34 -91.07 REMARK 500 ALA A 193 164.69 63.28 REMARK 500 MET A 208 59.81 -95.16 REMARK 500 ASP A 210 -150.30 -147.38 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 7EY A 401 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue CL A 402 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue CL A 403 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue CL A 404 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue CL A 405 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue CL A 406 DBREF 5M44 A 1 335 UNP P68400 CSK21_HUMAN 1 335 SEQRES 1 A 335 MET SER GLY PRO VAL PRO SER ARG ALA ARG VAL TYR THR SEQRES 2 A 335 ASP VAL ASN THR HIS ARG PRO ARG GLU TYR TRP ASP TYR SEQRES 3 A 335 GLU SER HIS VAL VAL GLU TRP GLY ASN GLN ASP ASP TYR SEQRES 4 A 335 GLN LEU VAL ARG LYS LEU GLY ARG GLY LYS TYR SER GLU SEQRES 5 A 335 VAL PHE GLU ALA ILE ASN ILE THR ASN ASN GLU LYS VAL SEQRES 6 A 335 VAL VAL LYS ILE LEU LYS PRO VAL LYS LYS LYS LYS ILE SEQRES 7 A 335 LYS ARG GLU ILE LYS ILE LEU GLU ASN LEU ARG GLY GLY SEQRES 8 A 335 PRO ASN ILE ILE THR LEU ALA ASP ILE VAL LYS ASP PRO SEQRES 9 A 335 VAL SER ARG THR PRO ALA LEU VAL PHE GLU HIS VAL ASN SEQRES 10 A 335 ASN THR ASP PHE LYS GLN LEU TYR GLN THR LEU THR ASP SEQRES 11 A 335 TYR ASP ILE ARG PHE TYR MET TYR GLU ILE LEU LYS ALA SEQRES 12 A 335 LEU ASP TYR CYS HIS SER MET GLY ILE MET HIS ARG ASP SEQRES 13 A 335 VAL LYS PRO HIS ASN VAL MET ILE ASP HIS GLU HIS ARG SEQRES 14 A 335 LYS LEU ARG LEU ILE ASP TRP GLY LEU ALA GLU PHE TYR SEQRES 15 A 335 HIS PRO GLY GLN GLU TYR ASN VAL ARG VAL ALA SER ARG SEQRES 16 A 335 TYR PHE LYS GLY PRO GLU LEU LEU VAL ASP TYR GLN MET SEQRES 17 A 335 TYR ASP TYR SER LEU ASP MET TRP SER LEU GLY CYS MET SEQRES 18 A 335 LEU ALA SER MET ILE PHE ARG LYS GLU PRO PHE PHE HIS SEQRES 19 A 335 GLY HIS ASP ASN TYR ASP GLN LEU VAL ARG ILE ALA LYS SEQRES 20 A 335 VAL LEU GLY THR GLU ASP LEU TYR ASP TYR ILE ASP LYS SEQRES 21 A 335 TYR ASN ILE GLU LEU ASP PRO ARG PHE ASN ASP ILE LEU SEQRES 22 A 335 GLY ARG HIS SER ARG LYS ARG TRP GLU ARG PHE VAL HIS SEQRES 23 A 335 SER GLU ASN GLN HIS LEU VAL SER PRO GLU ALA LEU ASP SEQRES 24 A 335 PHE LEU ASP LYS LEU LEU ARG TYR ASP HIS GLN SER ARG SEQRES 25 A 335 LEU THR ALA ARG GLU ALA MET GLU HIS PRO TYR PHE TYR SEQRES 26 A 335 THR VAL VAL LYS ASP GLN ALA ARG MET GLY HET 7EY A 401 22 HET CL A 402 1 HET CL A 403 1 HET CL A 404 1 HET CL A 405 1 HET CL A 406 1 HETNAM 7EY 3-[5-(4-METHYLPHENYL)THIENO[2,3-D]PYRIMIDIN-4- HETNAM 2 7EY YL]SULFANYLPROPANOIC ACID HETNAM CL CHLORIDE ION FORMUL 2 7EY C16 H14 N2 O2 S2 FORMUL 3 CL 5(CL 1-) FORMUL 8 HOH *11(H2 O) HELIX 1 AA1 ASP A 14 ARG A 19 1 6 HELIX 2 AA2 PRO A 20 ASP A 25 1 6 HELIX 3 AA3 TYR A 26 HIS A 29 5 4 HELIX 4 AA4 ASN A 35 ASP A 37 5 3 HELIX 5 AA5 LYS A 74 LEU A 88 1 15 HELIX 6 AA6 THR A 129 MET A 150 1 22 HELIX 7 AA7 LYS A 158 HIS A 160 5 3 HELIX 8 AA8 SER A 194 LYS A 198 5 5 HELIX 9 AA9 GLY A 199 VAL A 204 1 6 HELIX 10 AB1 TYR A 211 ARG A 228 1 18 HELIX 11 AB2 ASP A 237 GLY A 250 1 14 HELIX 12 AB3 THR A 251 TYR A 261 1 11 HELIX 13 AB4 ASP A 266 GLY A 274 1 9 HELIX 14 AB5 ARG A 280 VAL A 285 5 6 HELIX 15 AB6 SER A 294 LEU A 305 1 12 HELIX 16 AB7 THR A 314 GLU A 320 1 7 HELIX 17 AB8 HIS A 321 TYR A 323 5 3 HELIX 18 AB9 PHE A 324 GLN A 331 1 8 SHEET 1 AA1 5 TYR A 39 LYS A 44 0 SHEET 2 AA1 5 SER A 51 ASN A 58 -1 O GLU A 55 N ARG A 43 SHEET 3 AA1 5 GLU A 63 LEU A 70 -1 O VAL A 67 N PHE A 54 SHEET 4 AA1 5 ALA A 110 GLU A 114 -1 O PHE A 113 N VAL A 66 SHEET 5 AA1 5 LEU A 97 VAL A 101 -1 N ALA A 98 O VAL A 112 SHEET 1 AA2 3 LYS A 122 GLN A 123 0 SHEET 2 AA2 3 VAL A 162 ASP A 165 -1 O ILE A 164 N LYS A 122 SHEET 3 AA2 3 LYS A 170 LEU A 173 -1 O ARG A 172 N MET A 163 SHEET 1 AA3 2 ILE A 152 MET A 153 0 SHEET 2 AA3 2 GLU A 180 PHE A 181 -1 O GLU A 180 N MET A 153 CISPEP 1 GLU A 230 PRO A 231 0 -4.34 SITE 1 AC1 8 LEU A 45 VAL A 53 GLU A 55 ILE A 95 SITE 2 AC1 8 GLU A 114 HIS A 115 MET A 163 CL A 403 SITE 1 AC2 3 ARG A 155 TYR A 188 ASN A 189 SITE 1 AC3 4 LYS A 68 ILE A 95 ASP A 175 7EY A 401 SITE 1 AC4 2 PRO A 159 HIS A 160 SITE 1 AC5 2 HIS A 148 ALA A 315 SITE 1 AC6 3 LYS A 229 PHE A 232 HIS A 234 CRYST1 72.061 72.061 131.579 90.00 90.00 90.00 P 43 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013877 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013877 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007600 0.00000